Anti-VEGF remains most expensive PBS drug
The Australian government spent $55 million more on anti-VEGF macular disease therapies in 2020-21 compared to the previous year, with ...
The Australian government spent $55 million more on anti-VEGF macular disease therapies in 2020-21 compared to the previous year, with ...
The suppliers of two new anti-VEGF therapies recently cleared in the US that work to reduce macular disease treatment burdens ...
An independent expert panel has recommended Novartis' treatment Beovu be subsidised through the Pharmaceutical Benefits Scheme (PBS) for neovascular age-related ...
The first patient in the Phase 3 clinical trial of a Melbourne-based drug company’s novel therapy for neovascular age-related macular ...
The Australian government spent more than $610 million on anti-VEGF treatments during the past year, with aflibercept (Eylea) leapfrogging a ...
Melbourne biopharmaceutical company Opthea has received an $8.5 million research and development (R&D) tax credit from the Australian tax authority ...
For 40 years laser therapy has been the standard treatment for proliferative diabetic retinopathy (PDR), but now Australian ophthalmologists have ...
A Melbourne-based drug company is one step closer to starting Phase 3 clinical trials and pre-commercial development of its novel ...
A biopharmaceutical company that is developing cheaper anti-VEGF treatments for Australia and other markets has launched a global clinical trial ...
A biopharmaceutical company that is developing cheaper anti-VEGF treatments for major global markets, including Australia, has reported positive results from ...
Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.
© 2024 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited
© 2024 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited